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Galectin-3 is a β-galactoside binding lectin, containing carbohydrate-recognition domain, which interacts with a number of 
ligands. It is found in many tissues and is distributed intra– and extracellularly. The localization of the biomarker determines its 
function. Galectin-3 is involved in variety of biological processes sush as inflammation, fibrosis, immunological response and 
neoplastic growth. It may be used as a diagnostic or prognostic biomarker especially in cancer and cardiovascular diseases. 
The present review summarizes some of the properties of this biomarker. Biomed Rev 2019;30:83-88
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INTRODUCTION
Galectins	are	a	multifunctional	family	of	soluble	β-galactoside	
binding	 lectines,	 which	 play	 an	 important	 role	 in	 inflam-
mation,	 fibrosis,	 immunological	 response	 and	 neoplastic	
growth.	They	use	specific	carbohydrate-recognition	domain	
(CRD) to bind carbohydrate molecules (1). At present, 15 ga-
lectins	have	been	 identified,	which	are	classified	 into	 three	
subgroups, according to protein structure and domain organi-
zation (1, 2). The prototypical galectins, galectin-1, -2, -5, 
-7, -10, -11,-13, -14 and -15, contain single CRD. The tan-
dem-repeat galectins, galectin-4, -6, -8, -9 and -12, are with 
two CRD separated by a linker region in a single polypep-
tide chain. Galectin-3 (Gal-3) is the only chimera-type ga-
lectin,	which	contains	CRD	connected	to	flexible	non-lectin	
110-130 amino acids N-terminal domain, consisting of 7-14 
tandem short amino acid segments. It is a 29-35 kD protein. 
It interacts with a number of ligands – carbohydrates like 
N-acetylgalactosamin, and non glycosylated molecules like 
surface cell receptors (macrophages) and extracellular recep-
tors (collagen type IV). C-terminal domain is responsible for 
the	β-galactoside	binding	and	anti-apoptotic	activity	and	the	
presence of N-terminal domain is necessary for the secretion, 
translocation, multimerization of Gal-3 and also for the anti-
apoptotic activity (1-3). 
Galectin-3 is the best studied member of galectins family. 
In humans Gal-3 is distributed in many tissues, preferably 
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epithelia - skin, mucosa, epithelial lining of the digestive and 
respiratory tract, urothelium and excretory tubes of the kid-
ney,	in	the	myocardial	cells,	liver,	in	the	fibroblasts,	chondro-
cytes, osteoblasts, osteoclasts, keratinocytes and Schwann 
cells. Gal-3 is involved in immune response. It is expressed 
in neutrophils, eosinophils, basophils, mast cells, Langerhans 
cells, dendritic cells, monocytes and macrophages. The bio-
marker is found in a number of tumors and the expression 
reflects	the	tumor	characteristics.	Galectin-3	can	be	located	
intracellularly in the cytoplasm, nucleus and membrane and 
extracellularly. It is secreted in the interstitium and in the 
blood	flow	from	activated	macrophages	in	response	to	physi-
ological or pathophysiological stimuli . The different distri-
bution of Gal-3 is associated with its various functions.
ROLE OF GALECTIN-3 IN INFLAMMATION
Galectin-3	 participates	 in	 acute	 and	 chronic	 inflammation.	
Recent studies have demonstrated that Gal-3 can detect cer-
tain	 microbial	 structures	 by	 binding	 specific	 carbohydrate	
structures of glycoproteins and glycolipids from many patho-
gens	(3,	4).	It	acts	pro-inflammatory	stimulating	the	infiltra-
tion of neutrophils and other immune cells to the infected 
sites	 and	 inducing	 production	 of	 inflammatory	 cytokines	
from the macrophages . The biomarker can also be released 
in response to damage. Galectin-3 is synthesized and accu-
mulated in the cytoplasm of cells, separately from the glycan 
ligands. Different pathogens may trigger its secretion. It may 
be passively released from damages cells or actively secreted 
from activated cells by receptor engagement of cytokines 
(6). Galectin-3 is secreted through a leaderless pathway, 
which	requires	specific	amino-acid	sequence	close	to	the	N-
terminal portion of the protein. The release of Gal-3 from 
the damaged cells correlate with the level of virulence of the 
microorganism. There are data in mice that Gal-3 is exported 
to the alveoli when the microbic agent is pathogenic like S. 
pneumonia, but not in infection with E. coli, which is less 
pathogenic (6, 7). Galectin-3 can act as pattern-recognition 
receptor (PRR) in infectious diseases, caused by bacteria, 
viruses, fungi and parasites 10 . It interacts with microbial 
ligands by binding lipopolysaccharides (LPS). Studies on in-
fection with Escherichia coli and Pseudomonas aeruginosa 
reveal two independent binding sites on Gal-3 (8) . One is the 
carbohydrate binding site in the C-terminal domain, which 
interacts with beta-galactoside-containing polysaccharide 
chain. The other site is located on the N-terminal domain 
and binds to the inner core of LPS. Both interactions lead to 
oligomerization	of	Gal-3	and	induce	the	proinflammatory	ac-
tivity	on	the	neutrophils.	Macrophages	from	Gal-3-deficient	
mice produce more cytokines in response to LPS stimula-
tion. The process is suppressed by the addition of exogenous 
Gal-3, showing that galectin-3 is a natural negative modu-
lator for LPS function (7). Galectin-3 also recognizes and 
binds the mycolic acid from mycobacteria (7). This results 
in inhibition of oligomerization of Gal-3 but does not af-
fect the carbohydrate-binding abilities. Another mechanism 
of interaction is the accumulation of phagosomes, contain-
ing live mycobacteria, primarily at the cytosolic face of the 
phagosome membrane (7). The recognition of pathogenic 
fungi from Gal-3 is mediated by Dectin-1. It is a macrophage 
transmembrane lectin on the fungal cell wall, which is a re-
ceptor for b-glucans. Gal-3 binds to oligomannas on the cell 
wall. Macrophages must express both Dectin-1 and Gal-3 as 
in Candida albicans, to release a response. They secret tumor 
necrosis	 factor-α	 (TNF-α)	 in	 a	C.albicans-specific	manner	
through cross-talk with Toll-like receptor 2 (TLR2) . Addi-
tionally	binding	of	Gal-3	to	β-1,2	oligomannas	of	C. albicans 
kills fungi directly . Gal-3 has antimicrobial activity only to 
species,	containing	β-1,2	oligomannas.	Gal-3	interacts	with	
parasites like Leishmania (9, 10) and Trypanosoma (9) cruzi 
. The immunological response to infection with Leishma-
nia major	is	performed	through	specific	depletion	of	Gal-3.	
Binding of Gal-3 to the polygalactosyl repeats of Leishmania 
leads to truncation of Gal-3 by their surface major protease, 
gp63. The truncated Gal-3 cannot oligomerize or form stable 
Gal-3 association (9). Galectin-3 interacts with Trypanosoma 
cruzi	by	binding	three	specific	proteins	of	the	parasite.	The	
binding of  T. cruzi to human coronary artery smooth muscle 
cells is also Gal-3 dependent (10).
Galectin-3	plays	a	role	in	inflammation	also	in	noninfec-
tious	 conditions.	 Recently	 the	metabolic	 inflammation	 has	
raised	the	scientific	interest.	It	can	occur	as	a	result	of	adi-
pose tissue expansion in obesity and precedes the develop-
ment of insulin resistance, type 2 diabetes and nonalcoholic 
fatty liver disease . Galectin-3 participates in the pathogen-
esis of diabetic complications via its ability to bind advanced 
glycation end-products (AGEs) and advanced lipoxidation 
end-products (ALEs). Yilmaz et al found that Gal-3 levels 
were	significantly	higher	in	patients	with	diabetes	than	those	
without and higher in prediabetic than nondiabetic group . In 
the same study Gal-3 correlated with fasting plasma glucose 
(r = 0.787, P < 0.01), 2-hour plasma glucose (r = 0.833, P < 
0.01), CRP (r = 0.501, P < 0.01) and insulin resistance (HO-
85
Biomed Rev 30, 2019
Galectin-3 in the clinic
MA-IR) index (r = 0.518, P < 0.01). A small study showed 
higher levels of Gal-3 in patients with gout, but further re-
search is needed (11).
ROLE OF GALECTIN-3 IN CANCER
Galectin-3 is implicated in carcinogenesis and tumor pro-
gression through different mechanisms. In cancer, it has both 
intracellular and extracellular functions. The glycoprotein 
participates in cell proliferation, adhesion, differentiation, 
angiogenesis and apoptosis in normal and pathologic tissues. 
It impacts the tumor cell transformation, migration, invasion 
and metastasis (12).
Overexpression of Gal-3 is found in many cancers and it 
has the potential to be used as an oncological biomarker for 
diagnosis. There is evidence that Gal-3 over expression is as-
sociated with neoplastic transformation (11, 12). Suppression 
of Gal-3 in breast carcinoma cells causes a reversion of the 
transformed phenotype as determined by altered morpholo-
gy, loss of serum-independent growth, acquisition of growth 
inhibition properties by cell contact, and abrogation of an-
chorage-independent growth . Thyroid papillary carcinoma 
cells lose their characteristic transformed phenotypes in cell 
culture after inhibition of Gal-3 expression . The transfection 
of Gal-3 cDNA into normal thyroid follicular cells induced 
serum-independent growth, clonogenicity in soft agar and 
loss of contact inhibition . The resistance of tumor cells to 
apoptosis plays an important role for the tumor malignancy 
and progression. It is shown that Gal-3 has an anti-apoptotic 
and/or pro-apoptotic features in different cell types and lo-
calizations . Several regulatory pathways for the antiapop-
totic activity are discussed. In response to apoptotic stimuli 
galectin-3 translocates from the cytosol or the nucleus to the 
perinuclear mitochondrial membrane, prevents mitochon-
drial damage and suppresses cytochrome c release. This 
process leads to down-regulation of caspase activation . The 
phosphorylation of Gal-3 at position Ser6 also contributes 
for the anti-apoptotic activity. Other possible mechanisms 
are the activation of ERK and JNK (c-Jun NH2-terminal 
kinase) pathways  and interaction with CD95 (APO-1/Fas) 
receptor . Extracellular Gal-3 is found to have pro-apoptotic 
activity in human leukemia cell lines and human peripheral 
blood mononuclear cells . Galectin-3 participates in the im-
mune	regulation	and	thus	influences	immunosuppression	in	
tumorogenesis. It acts by suppressing CD8+ cells via LAG-3 
and inhibiting expansion of plasmocytoid dendritic cells in 
patients with pancreatic ductal adenocarcinoma . In combi-
nation	with	 soluble	 fibrinogen	Gal-3	 is	 found	 to	modulate	
the functionality and life-span of the neutrophils . Galectin-3 




heterotypic tumor cell adhesion to endothelial cells by bind-
ing to cancer associated TF/MUC1 and mediates homotypic 
aggregation of tumor cells forming tumor micro-emboli and 
invading blood vessels to reach distant organ sites (23, 24).. 
Angiogenesis is essential for tumor invasion and metastasis. 
It is suggested that Gal-3 modulates vascular endothelial 
growth	 factor-	 and	 basic	 fibroblast	 growth	 factor-mediated	
angiogenesis (25). Another study showed regulation of an-
giogenic and migratory response in endothelial cells via 
modulation of integrin-linked kinase signaling (26).. An 
interaction of Gal-3 with endothelial cell surface enzyme 
aminopeptidase	N/CD13	has	also	been	reported	to	influence	
endothelial vascularization in the early steps of angiogenesis 
(27).. Galectin-3 overexpression in the tumor caused mac-
rophage	 infiltration	 and	 acceleration	 of	 angiogenesis	 (28)..	
Because	Gal-3	reflects	dynamic	changes	in	cancer	status,	it	
may be used not only as marker of diagnosis, but also as a 
marker of cancer progression and prognosis \29)..
ROLE OF GALECTIN-3 IN CARDIOVASCULAR DISEASES
Galectin-3	as	a	marker	of	fibrosis	and	inflammation	plays	an	
important role in cardiovascular diseases. It is found at the 
site	of	fibrosis	together	with	fibroblasts	and	macrophages	29. 
In	vitro	experiments	on	cultures	of	cardiac	fibroblasts	show	
that Gal-3 induces proliferation and synthesis of collagen  . It 
is	a	potent	mitogenic	factor	for	fibroblasts,	affects	synthesis	
of	new	matrix	components	as	collagen	type	1	and	influences	
the degradation of components of extracellular matrix by 
metalloproteinases.
Galectin-3	has	not	only	prognostic	significance,	but	is	also	
a target for acute and chronic intervention. The participation 
of	Gal-3	in	the	progression	of	heart	failure	(HF)	is	first	stud-
ied in animals by Sharma et al (12). Higher levels of the pro-
tein	were	found	 in	patients	with	severe	cardiac	fibrosis.	To	
determine	whether	Gal-3	is	directly	associated	with	fibrosis,	
it was injected intrapericardial in normal murine hearts. This 
led to reduction of left ventricle ejection fraction (LV EF), 
higher LV mass and abundance of collagen type I in compari-
son	with	placebo.	These	 results	 are	 confirmed	with	human	
myocardial biopsy, where higher levels of Gal-3 correlated 
with lower LV EF. 
Galectin-3 is studied in a number of cardiovascular clini-
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cal trials. It predicts the all cause mortality in the general 
population and the levels correlate positively with age and 
cardiovascular risk factors as diabetes, smoking, angina, 
hypertension, obesity and hyperlipidemia. This is more pro-
nounced in females in PREVEND (Prevention of Renal and 
Vascular End-stage Disease) study . Results of PROVE-IT 
TIMI (Pravastatin or Atorvastatin Evaluation and Infection 
Therapy – Thrombolysis in Myocardial Infarction) show that 
Gal-3 is associated with higher risk of developing HF after 
acute coronary syndrome (33).. In DEAL-HF (Deventer–
Alkmaar heart failure) Gal-3 was an independent predictor 
for mortality in patients with moderate and severe HF. The 
levels of Gal-3 were associated with age, renal function and 
HF severity (34).. Sub analysis of COACH (Coordinating 
Study on Outcomes of Advising and Counselling in Heart 
Failure) trial demonstrated that Gal-3 is an independent 
prognostic marker for HF and may be especially useful in 
HF with reduced EF (32).  . In the same study patients with 
higher Gal-3 levels were more likely to suffer from diabetes 
or	atrial	fibrillation	(AF).	
Routine measurement of Gal-3 in HF patients has a number 
of	benefits	 4.	Heart	 failure	may	be	divided	 into	 two	groups	
according to involvement of Gal-3 in the pathogenesis. Galec-
tin-3	mediated	HF	is	characterized	with	high	activity	of	fibro-
genesis, progressive course and high risk of adverse outcome. 
The other group is with heterogenic etiology and pathology, 
slow progression and low risk of adverse outcome (35). Gal-3 
is complementary to brain natriuretic peptides (BNP), but is 
independent predictor. Patients with increase of both biomark-
ers have the worst outcome (36).. Most of the biomarkers as 
BNP and CRP are released in the circulation as a result of cell 
damage. In contrast, Gal-3 is found in the extracellular matrix 
and plays a causative role in the remodeling process. Its inhi-
bition	may	stop	or	regress	the	fibrosis.	Galectin-3	testing	by	
enzyme-linked immune-sorbent assay (ELISA) is approved by 
the US Food and Drug Administration (FDA) in chronic heart 
failure patients and is included in the guidelines (37).
The hallmark of AF is structural remodeling due to pro-in-
flammatory	and	profibrotic	changes	in	the	atrial	tissue,	which	
supposes an association between Gal-3 and AF. Data from 
Framingham study derived from 3 000 patients show that 
higher circulating levels of Gal-3 may predict AF (37).. The 
prevalence	of	AF	was	higher	according	to	age	specific	quar-
tiles – 3,7%, 5,9%, 9,1% and 11,5% respectively in 10 years, 
but	after	adjusting	for	traditional	risk	factor	the	significance	
is lost. Similar are the results of Somnez et al (38). They 
found higher levels of Gal-3, matrix metalloproteinases and 
type III procollagen peptide in AF patients. Studies about the 
role of Gal-3 as a prognostic marker for AF recurrences after 
catheter ablation are controversial. Wu et al measured higher 
Gal-3 levels in patients with persistent AF without struc-
tural heart disease and demonstrated that the biomarker sig-
nificantly	predicts	AF	recurrence	after	ablation	(39)..	Kornej	
et al also found higher values of Gal-3 in AF patients, but 
thought this is attributable to the accompanying cardiometa-
bolic diseases, but not to the arrhythmia itself. They conclude 
that Gal-3 cannot predict AF recurrence after ablation (40).. 
Galectin-3 could be the new target for upstream therapy in 
AF,	because	it	is	a	mediator	of	atrial	fibrosis,	which	induces	
an anisotropic conductance in the atria  (41).. A couple of 
studies show correlation between Gal-3 and thromboembolic 
risk as assessed by CA2DS2Vasc score (42-44). .
CONCLUSION
Galectin-3 is expressed intra- and extracellularly in various 
tissues. It is involved in multiple biological processes, such 
as	 inflammation,	 oncogenesis,	 tumor	 progression,	metasta-
sis	 and	 angiogenesis.	Because	 of	 its	 pro-inflammatory	 and	
profibrotic	activity,	Gal-3	 is	used	as	a	marker	of	prognosis	
in oncological and cardiovascular diseases, especially in HF 
and AF. More studies are needed to found the utility of the 
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